Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Amanda Cashen, Mark Juckett, Alcee Jumonville, Mark Litzow, P. J. Flynn, John Eckardt, Betsy LaPlant, Kristina Laumann, Charles Erlichman, John DiPersio

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).'. Together they form a unique fingerprint.

Medicine & Life Sciences